What is Phosphorus?
Phosphorus operates as a comprehensive genomics-as-a-service provider, distinguishing itself through a fully verticalized infrastructure that spans from initial laboratory chemistry to advanced software analytics. By democratizing access to high-fidelity genetic testing, the company empowers healthcare providers to transition from reactive treatment models to proactive, preventative health strategies. Their white-labeling capabilities allow diverse organizations to deploy customized genomic solutions, effectively scaling the reach of personalized medicine across the broader healthcare ecosystem. This strategic positioning allows Phosphorus to serve as a foundational layer for modern wellness and clinical diagnostics.
How much funding has Phosphorus raised?
Phosphorus has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2016): $10M with participation from FirstMark Capital
Key Investors in Phosphorus
FirstMark Capital
FirstMark Capital is a New York-based venture firm that focuses on early-stage investments in technology and information management, providing strategic guidance to high-growth companies.
What's next for Phosphorus?
With the recent influx of capital, Phosphorus is expected to deepen its investment in bioinformatics and laboratory automation to further optimize its service delivery. The company's roadmap likely involves expanding its white-label partnerships, enabling more healthcare institutions to integrate preventative genomics into their standard patient offerings. As the firm scales, the focus will remain on maintaining medical-grade accuracy while driving down costs, a dual-pronged approach that is essential for achieving widespread adoption in the clinical market. Future growth will be defined by the company's ability to navigate the regulatory landscape while continuing to innovate within the rapidly maturing field of genomic health.
See full Phosphorus company page
